Michael Anthony Siem

Michael Siem is a nationally renowned intellectual property litigator and registered patent attorney with a focus on complex and high-value patent litigation. He represents both patentees and alleged infringers.

Michael regularly appears before various federal district courts and has litigated cases in many technological areas, including pharmaceuticals, consumer electronics, chemical processes, computer networks, and biotechnology. His experience encompasses every aspect of litigation, beginning with the pre-suit investigation and continuing through trial.

Equipped with a deep understanding of pharmaceutical litigation related to intellectual property and the Hatch-Waxman Act, Michael currently serves as lead trial counsel in several ongoing matters representing some of the largest pharmaceutical manufacturers in the world. These matters pertain to Abbreviated New Drug Applications (ANDAs) for pharmaceutical products that utilize substances including fingolimod, bendamustine hydrochloride, and permetrexed, among many others, and involve the treatment of conditions including relapsing multiple sclerosis, chronic lymphocytic leukemia, advanced nonsquamous non-small cell lung cancer, and malignant pleural mesothelioma. In addition, Michael has extensive experience with the Biologic Price Competition and Innovation Act (BPCIA), preparing his clients for litigation and licensing of their technology.  He is also a frequent lecturer on the BPCIA.

Michael’s experience extends far beyond the pharmaceutical and technology industries into other areas of intellectual property law. He has handled trademark litigation under the Anticybersquatting Consumer Protection Act related to the use and registration of a website domain name. He also has significant experience in drafting and filing patent and trademark applications.

Michael dedicates a significant portion of his time to pro bono matters. In 2010 Michael obtained a reversal and new sentencing hearing in the Virginia Supreme Court for a client who had received a death sentence. Michael was also lead counsel in a challenge to the constitutionality of lethal injection in the State of Georgia, and obtained an indefinite stay of execution on October 18, 2007 for his client. In recognition of these efforts, Michael was a recipient of the 2008 Thurgood Marshall Award for Capital Representation, given by the Committee on Capital Punishment of the Association of the Bar of the City of New York.

While earning his law degree at the University of Michigan Law School, Michael served as associate editor of the Michigan Telecommunications and Technology Law Review. Michael graduated from the Illinois Institute of Technology with a B.S. in chemical engineering.